logo

Press Journals

OX-40 Receptor Emerging as a Novel Target in Cancer Immunotherapy

October 2017

OX-40 receptor agonist currently exhibits a viable pipeline with nine drug candidates, P&S Market Research

OX-40 receptor agonist therapeutics pipeline in 2017

The study analyzed that the OX-40 receptor agonist therapeutics pipeline comprises approximately nine drug candidates in different stages of development. OX-40 is a costimulatory receptor that binds to its only known ligand, OX-40L, initiating cellular signaling events required for full activation of T cells following their recognition of a foreign antigen. OX-40 agonists mimic the effect of OX-40L, and boost the OX-40 signaling, and thereby leads to the suppression of the anti-tumor immune response in cancer patients. OX-40 agonists in combination with checkpoint immunotherapies, surgical resection, and radiotherapy has demonstrated promising results for the treatment of cancer patients.

Access Report Summary with Detailed TOC on “OX-40 Receptor Agonist Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline 


Insights on pipeline segments

According to the research findings, most of the drug candidates of OX-40 receptor agonist therapeutics pipeline are being developed as a monoclonal antibody.

Maximum drugs being developed as monoclonal antibody

Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.

Various collaborations for OX-40 receptor agonist drug development

In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.

OX-40 Receptor Agonist Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company